What does STEDIPHAR do?

STEDIPHAR is a pharmacy in Oostende. Private Limited, started on 11 March 2002, 1 establishment.

What is the address of STEDIPHAR?

The registered office of STEDIPHAR is located at Nieuwpoortsesteenweg 70, 8400 Oostende.

Is STEDIPHAR still active?

Yes. According to the CBE (29 October 2026) STEDIPHAR is active, legal situation “Normale toestand”, started on 11 March 2002.

Is STEDIPHAR registered on Peppol?

Yes, STEDIPHAR is registered on the Peppol network with ID 0208:0477059361.

What is the enterprise number of STEDIPHAR?

The enterprise number of STEDIPHAR is BE0477059361.

When was STEDIPHAR founded?

STEDIPHAR was founded on 11 March 2002.

Who are the directors of STEDIPHAR?

According to the 2025 annual accounts, the directors of STEDIPHAR are: MEULEMEESTER STEVEN BV, MEULEMEESTER DIDRIK BV.

Is STEDIPHAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 March 2002; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did STEDIPHAR make in 2025?

STEDIPHAR posted a profit after taxes of € 207,443 in financial year 2025.

What is the revenue of STEDIPHAR?

As a small company, STEDIPHAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 391,214.

How much does an employee at STEDIPHAR earn?

The average wage cost per full-time employee at STEDIPHAR was € 76,700 in 2025: staff costs of € 145,753 for 1.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does STEDIPHAR have?

According to the 2025 annual accounts, STEDIPHAR has 1.9 full-time equivalents (FTE).

STEDIPHAR (Private Limited) - Oostende - BE0477059361

Dossier STEDIPHAR, printed on 29 October 2026 from databakkes.be/en/0477059361/stediphar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

STEDIPHAR from Oostende, company number BE0477059361, closed financial year 2025 with a result of € 207,443 after tax. For that financial year STEDIPHAR recorded a gross margin of € 391,214 and equity of € 325,335. Compared with financial year 2024, the result moved from € 226,168 to € 207,443. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.

What it is worth Growing

€ 325,335

▲ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 207,443

▼ 8% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 53,865

▼ 92% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 178,000 paid out

86 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

1.9

▲ 0.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 145,753

▲ 31% vs 2024

€ 76,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,923

▼ 32% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 10,105

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 344,469

▼ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,429

▼ 46% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 319,296 Gross margin 2022: € 319,296 First fiscal year in the series	€ 273,695 Gross margin 2023: € 273,695 ▼ 14% vs 2022 (€ 319,296) Unfavourable step	€ 350,070 Gross margin 2024: € 350,070 ▲ 28% vs 2023 (€ 273,695) Favourable step	€ 391,214 Gross margin 2025: € 391,214 ▲ 12% vs 2024 (€ 350,070) Favourable step	▲ 12%
Profit after taxes	€ 329,136 Profit after taxes 2022: € 329,136 First fiscal year in the series	€ 214,271 Profit after taxes 2023: € 214,271 ▼ 35% vs 2022 (€ 329,136) Unfavourable step	€ 226,168 Profit after taxes 2024: € 226,168 ▲ 6% vs 2023 (€ 214,271) Favourable step	€ 207,443 Profit after taxes 2025: € 207,443 ▼ 8% vs 2024 (€ 226,168) Unfavourable step	▼ 8%
Equity	€ 216,100 Equity 2022: € 216,100 First fiscal year in the series	€ 264,371 Equity 2023: € 264,371 ▲ 22% vs 2022 (€ 216,100) Favourable step	€ 297,892 Equity 2024: € 297,892 ▲ 13% vs 2023 (€ 264,371) Favourable step	€ 325,335 Equity 2025: € 325,335 ▲ 9% vs 2024 (€ 297,892) Favourable step	▲ 9%
Total debts	€ 862,222 Total debts 2022: € 862,222 First fiscal year in the series	€ 1,570,437 Total debts 2023: € 1,570,437 ▲ 82% vs 2022 (€ 862,222) Unfavourable step	€ 1,004,610 Total debts 2024: € 1,004,610 ▼ 36% vs 2023 (€ 1,570,437) Favourable step	€ 760,475 Total debts 2025: € 760,475 ▼ 24% vs 2024 (€ 1,004,610) Favourable step	▼ 24%
Cash	€ 578,347 Cash 2022: € 578,347 First fiscal year in the series	€ 159,284 Cash 2023: € 159,284 ▼ 72% vs 2022 (€ 578,347) Unfavourable step	€ 708,064 Cash 2024: € 708,064 ▲ € 548,780 vs 2023 (€ 159,284) Favourable step	€ 53,865 Cash 2025: € 53,865 ▼ 92% vs 2024 (€ 708,064) Unfavourable step	▼ 92%
Land & buildings	€ 38,123 Land & buildings 2022: € 38,123 First fiscal year in the series	€ 36,813 Land & buildings 2023: € 36,813 ▼ 3% vs 2022 (€ 38,123) Unchanged	€ 35,082 Land & buildings 2024: € 35,082 ▼ 5% vs 2023 (€ 36,813) Unchanged	€ 33,970 Land & buildings 2025: € 33,970 ▼ 3% vs 2024 (€ 35,082) Unchanged	▼ 3%
Retained profit	€ 197,500 Retained profit 2022: € 197,500 First fiscal year in the series	€ 245,771 Retained profit 2023: € 245,771 ▲ 24% vs 2022 (€ 197,500) Favourable step	€ 279,292 Retained profit 2024: € 279,292 ▲ 14% vs 2023 (€ 245,771) Favourable step	€ 306,735 Retained profit 2025: € 306,735 ▲ 10% vs 2024 (€ 279,292) Favourable step	▲ 10%
Dividend	€ 281,400 Dividend 2022: € 281,400 First fiscal year in the series	€ 166,000 Dividend 2023: € 166,000 ▼ 41% vs 2022 (€ 281,400) Unchanged	€ 191,400 Dividend 2024: € 191,400 ▲ 15% vs 2023 (€ 166,000) Unchanged	€ 178,000 Dividend 2025: € 178,000 ▼ 7% vs 2024 (€ 191,400) Unchanged	▼ 7%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 10,105 Bank debt 2025: € 10,105 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 1,078,322 Balance sheet total 2022: € 1,078,322 First fiscal year in the series	€ 1,834,809 Balance sheet total 2023: € 1,834,809 ▲ 70% vs 2022 (€ 1,078,322) Unchanged	€ 1,302,501 Balance sheet total 2024: € 1,302,501 ▼ 29% vs 2023 (€ 1,834,809) Unchanged	€ 1,085,810 Balance sheet total 2025: € 1,085,810 ▼ 17% vs 2024 (€ 1,302,501) Unchanged	▼ 17%
Employees (FTE)	1.5 Employees (FTE) 2022: 1.5 First fiscal year in the series	1.5 Employees (FTE) 2023: 1.5 Unchanged (1.5) Unchanged	1.5 Employees (FTE) 2024: 1.5 Unchanged (1.5) Unchanged	1.9 Employees (FTE) 2025: 1.9 ▲ 0.4 vs 2024 (1.5) Unchanged	▲ 0.4

Key figures of STEDIPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to STEDIPHAR?

What happened at STEDIPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 27, 2026 New annual accounts for financial year 2025: profit of € 207,443 (▼ 8% vs 2024). filed late Source: NBB ↗
Nov 13, 2002 New establishment in Oostende. KBO
Mar 11, 2002 Start of the company according to the CBE. KBO

In short

From € 329,136 profit in 2022 to € 207,443 profit in 2025.

Paid € 83,598 in corporate taxes since 2022.

Best year ever: 2022, with € 329,136 profit.

On average € 205,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

MEULEMEESTER STEVEN BV MEULEMEESTER DIDRIK BV

Farmadistri

Bobbie Pharmaceutical Services

FARMAZORG

STEDIPHAR

Behind STEDIPHAR are MEULEMEESTER STEVEN BV and MEULEMEESTER DIDRIK BV. The same people are also behind Farmadistri, Bobbie Pharmaceutical Services, FARMAZORG and DISTEPHAR. MEULEMEESTER STEVEN BV is also behind MEDIPACK.

Directors

According to the 2025 annual accounts

MEULEMEESTER STEVEN BV

Administrator-manager · represented by STEVEN WIM MEULEMEESTER

Also active at: Farmadistri, Bobbie Pharmaceutical Services, FARMAZORG, DISTEPHAR, MEDIPACK

MEULEMEESTER DIDRIK BV

Administrator-manager · represented by DIDRIK MEULEMEESTER

Also active at: Farmadistri, Bobbie Pharmaceutical Services, FARMAZORG, DISTEPHAR

Establishments

Establishment units

Physical locations of this company

Registered office

Nieuwpoortsesteenweg 70

8400 Oostende

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0477.059.361

VAT number

BE 0477.059.361

Registered office

Nieuwpoortsesteenweg 70, 8400 Oostende

Names & denominations

STEDIPHAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

11 March 2002

Peppol

Active · Active since 15 Jul 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

STEDIPHAR

Financials

What happened to STEDIPHAR?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions